3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Fluorouracil
37
Radiotherapy
31
Oxaliplatin
29
Cisplatin
28
Paclitaxel
24
Leucovorin
22
Irinotecan
19
Docetaxel
13
pembrolizumab
10
Capecitabine
10
Carboplatin
9
Radiation
8
Neoadjuvant Therapy
8
Cetuximab
8
Surgical Procedures, Operative
7
Folfox protocol
7
Chemotherapy, Adjuvant
6
Nivolumab
5
Gefitinib
5
Taxes
4
Erlotinib Hydrochloride
4
Biopsy
4
durvalumab
3
Panitumumab
3
Itraconazole
3
Epirubicin
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma Of Esophagus
×
zimberelimab
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled